180 related articles for article (PubMed ID: 20851537)
21. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
Bröker M; Veitch K
Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
[TBL] [Abstract][Full Text] [Related]
22. Foresight in medicine: current challenges with Haemophilus influenzae type b conjugate vaccines.
Eskola J
J Intern Med; 2010 Mar; 267(3):241-50. PubMed ID: 20201918
[TBL] [Abstract][Full Text] [Related]
23. The promise of conjugate vaccines for Africa.
Kieny MP; LaForce FM
Vaccine; 2007 Sep; 25 Suppl 1():A108-10. PubMed ID: 17548136
[TBL] [Abstract][Full Text] [Related]
24. Prevention of meningococcal serogroup C disease by NeisVac-C.
Borrow R; Findlow J
Expert Rev Vaccines; 2009 Mar; 8(3):265-79. PubMed ID: 19249967
[TBL] [Abstract][Full Text] [Related]
25. [Polysaccharide vaccines against Haemophilus influenzae type B].
Wysokińska T; Janaszek W
Przegl Epidemiol; 1994; 48(1-2):39-44. PubMed ID: 8073141
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
27. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease.
Hallander HO; Lepp T; Ljungman M; Netterlid E; Andersson M
APMIS; 2010 Nov; 118(11):878-87. PubMed ID: 20955461
[TBL] [Abstract][Full Text] [Related]
28. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
[TBL] [Abstract][Full Text] [Related]
29. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
Khatami A; Snape MD; John T; Westcar S; Klinger C; Rollinson L; Boutriau D; Mesaros N; Wysocki J; Galaj A; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2011 Mar; 30(3):197-202. PubMed ID: 20844459
[TBL] [Abstract][Full Text] [Related]
30. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
[TBL] [Abstract][Full Text] [Related]
31. Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in vaccinated children who developed Haemophilus disease.
Weinberg GA; Murphy TV; Granoff DM
Pediatrics; 1990 Oct; 86(4):617-20. PubMed ID: 2216629
[No Abstract] [Full Text] [Related]
32. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
34. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
35. Bacterial meningitis: the impact of vaccination.
Makwana N; Riordan FA
CNS Drugs; 2007; 21(5):355-66. PubMed ID: 17447825
[TBL] [Abstract][Full Text] [Related]
36. The Meningitis Vaccine Project.
LaForce FM; Konde K; Viviani S; Préziosi MP
Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
38. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.
Pollard AJ; Perrett KP; Beverley PC
Nat Rev Immunol; 2009 Mar; 9(3):213-20. PubMed ID: 19214194
[TBL] [Abstract][Full Text] [Related]
39. Conjugate vaccines--a breakthrough in vaccine development.
Mäkelä PH
Southeast Asian J Trop Med Public Health; 2003 Jun; 34(2):249-53. PubMed ID: 12971544
[TBL] [Abstract][Full Text] [Related]
40. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.
Black SB; Shinefield HR
Pediatr Infect Dis J; 1992 Aug; 11(8):610-3. PubMed ID: 1523069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
